Get the Stockscreener App
3.24
10.20%
0.30
After Hours:
3.28
0.04
+1.23%
Ac Immune Sa stock is traded at $3.24, with a volume of 143.63K.
It is up +10.20% in the last 24 hours and down -4.14% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.94
Open:
$3.08
24h Volume:
143.63K
Relative Volume:
1.58
Market Cap:
$315.62M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-3.7939
EPS:
-0.854
Net Cash Flow:
$-68.17M
1W Performance:
+7.64%
1M Performance:
-4.14%
6M Performance:
+35.56%
1Y Performance:
+19.12%
1-Day Range:
$3.02
$3.28
1-Week Range:
$2.80
$3.28
52-Week Range:
$2.25
$5.14
Ac Immune Sa Stock (ACIU) Company Profile
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune: Q3 Earnings Snapshot - San Francisco Chronicle
AC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year - TipRanks
AC Immune SA Reports Profitable Q3 2024 Results - TipRanks
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Assenagon Asset Management S.A. Has $846,000 Stock Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat
Short Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4% - MarketBeat
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29% - Yahoo Finance
What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings - Yahoo Finance
Roche leaves Alzheimer partnership with UCB - European Biotechnology News
UCB Assessing Bepranemab’s Future After Roche/Genentech Ends Partnership - Citeline
AC Immune SA (NASDAQ:ACIU) Sees Significant Increase in Short Interest - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 12.9% in September - MarketBeat
AC Immune (NASDAQ:ACIU investor three-year losses grow to 47% as the stock sheds US$40m this past week - Simply Wall St
Will ABATE Trial Data Lift AC Immune's Stock Price? - RTTNews
Renaissance Technologies LLC Has $2.60 Million Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com - Defense World
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to Hold - MarketBeat
Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA - Barchart
CompleCure, AGC Biologics Partner To Develop Advanced Anti-Cancer Therapy - Contract Pharma
CompleCure Partners with AGC Biologics’ Chiba Site to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology - AccessWire
Why Industry Must Design Alzheimer's Trials To Include People With Down Syndrome - Clinical Leader
Investment Analysts’ Upgrades for September 23rd (ACIU, APD, BBY, BLD, CIGI, DQ, EBR, GFF, HBNC, KOPN) - Defense World
AGC Biologics and CompleCure Collaborate on Innovative Breast Cancer Treatment - Vancity Buzz
Bulls beat South and advance to Australia Cup final - MSN
Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
AC Immune SA Welcomes New CMO Dr. Anke Post - TipRanks
AC Immune (NASDAQ:ACIU) Given Buy Rating at HC Wainwright - Defense World
Investment Analysts’ Updated EPS Estimates for September 18th (ACIU, ADAG, AMS, AOSL, BDTX, BRCC, CFLT, CGEM, CMP, COR) - Defense World
AC Immune (NASDAQ:ACIU) Earns Buy Rating from HC Wainwright - MarketBeat
AC Immune shares hold as analyst reiterates price target - Investing.com
AC Immune secures milestone payment for Alzheimer's trial - Investing.com
AC Immune Advances in Alzheimer’s Trial, Secures Funding - TipRanks
AC Immune receives second milestone payment for ACI-35.030 - TipRanks
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease - Yahoo Finance UK
A novel class of drug candidates for neurodegenerative diseases - Drug Target Review
FDA Action Update, August 2024: Approvals, Designations, and Clearances - Neurology Live
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions - Yahoo Finance UK
AC Immune SA (NASDAQ:ACIU) Short Interest Update - MarketBeat
FDA grants fast track designation to Life Molecular Imaging’s tau PET diagnostic - Clinical Trials Arena
AC Immune's Tau-PET diagnostic gets FDA fast track - Investing.com
AC Immune’s Diagnostic Achieves FDA Fast Track Status - TipRanks
FDA grants AC Immune’s PI-2620 Tau-PET diagnostic fast track designations - TipRanks
Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World
The past three years for AC Immune (NASDAQ:ACIU) investors has not been profitable - Yahoo Finance
Assenagon Asset Management S.A. Purchases 328,312 Shares of AC Immune SA (NASDAQ:ACIU) - MarketBeat
AC Immune (NASDAQ:ACIU) Shares Cross Below 50-Day Moving Average of $3.84 - MarketBeat
AC Immune (NASDAQ:ACIU) Share Price Passes Below Fifty Day Moving Average of $3.84 - Defense World
HC Wainwright Equities Analysts Raise Earnings Estimates for AC Immune SA (NASDAQ:ACIU) - Defense World
Q3 2024 EPS Estimates for AC Immune SA Cut by Analyst (NASDAQ:ACIU) - Defense World
HC Wainwright Brokers Raise Earnings Estimates for AC Immune SA (NASDAQ:ACIU) - MarketBeat
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):